Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Symtuza Rapid Initiation in Newly Diagnosed HIV-1
NCT03227861Phase 3Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Scientific Affairs. Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 (FDA Snapshot). Started Jul 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03227861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227861.